Sio Gene Therapies founder Vivek Ramaswamy (JPM20)

Ax­o­vant-turned-Sio ditch­es two re­main­ing pro­grams, lays off most em­ploy­ees and will seek a buy­er

A year and a half ago, Sio Gene Ther­a­pies at­tempt­ed to steer in­to a new his­to­ry, with then-CEO Pa­van Cheru­vu telling End­points News it was “not a vant any longer” af­ter break­ing away from the Ax­o­vant name, of the Roivant de­scent.

The com­pa­ny might be get­ting a re­brand again soon. That is: Sio is look­ing for a new own­er, or an­oth­er com­pa­ny to merge with as the biotech is shut­ter­ing work on its two re­main­ing pro­grams, for GM1 and GM2 gan­gliosi­do­sis, or Tay-Sachs and Sand­hoff dis­ease. SVB Se­cu­ri­ties will help the com­pa­ny find a new path for­ward.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.